TwinTrader.com Announces the Initiation of Profile Coverage for China Biopharmaceuticals Holdings, Inc.


DALLAS, Jan. 19, 2006 (PRIMEZONE) -- Reggie Sanchez, President of TwinTrader.com, announced Profile Coverage of China Biopharmaceuticals Holdings, Inc. (OTCBB:CHBP) (China Biopharmaceuticals). Operating in China, China Biopharmaceuticals is focused on advanced drug discovery and development tools able to analyze the chemical compounds and natural substances of new drugs and traditional Chinese medicines.

Reggie Sanchez and Scott Sanchez each spoke of China Biopharmaceuticals:

Scott: "China Biopharmaceuticals' main focus is on developing and commercializing innovative drugs in China, operating from a solid base of integrated resources and capabilities."

Reggie: "China Biopharmaceuticals' integrated R&D team is very advanced and experienced, and its technology platforms represent robust drug discovery potential."

Scott: "The pharmaceutical industry is one of the largest and fastest growing sectors in China's economy. China Biopharmaceuticals is right where it needs to be."

Reggie: "With its product pipeline, proprietary technology, highly advanced R&D team and recent acquisitions, China Biopharmaceuticals is definitely worth the look."

To view the Twin Trader profile for China Biopharmaceuticals Holdings, Inc. please visit:

www.twintrader.com/profile/chbp/

About TwinTrader.com

TwinTrader.com features the best of the small cap and microcap markets. In addition to "offensive play" and "defensive plays" for members, TwinTrader features Profiles of key companies. Reggie Sanchez and Scott Sanchez, the Twin Traders, give their take on each and every profiled company.

To feature your publicly traded company in our alerts, or to discuss our complete services, please contact Reggie Sanchez by telephone at (214) 227-7559 or by e-mail at Reggie@TwinTrader.com. You may also contact Scott Sanchez by telephone at (214) 227-7560 or by e-mail at Scott@TwinTrader.com.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of China Biopharmaceuticals Holdings, Inc. ("the Company") ("CBH") or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its plan of operations when needed; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings."

Disclosure: TwinTrader LLC was compensated $10,500 by a third party for profile coverage. TwinTrader LLC are not registered investment advisers or broker/dealers. TwinTrader LLC makes no recommendation that the purchase of securities of companies profiled in this Web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.



            

Contact Data